CGRP 8-37 (rat) |
Catalog No.GC10927 |
CGRP 8-37 (rat) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 129121-73-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats: Adult male Sprague Dawley rats are given a spinal hemisection or a sham surgery at the T13 spinal segment. An externally accessible PE-10 intrathecal catheter that terminated at T13 is used for drug delivery. Animals are allowed to recover for 4 weeks at which time the hemisected animals displayed mechanical and thermal allodynia bilaterally, in both forelimbs and hindlimbs. CGRP-(8-37) is delivered just prior to a testing session in 1, 5, 10, or 50 nM doses in artificial cerebral spinal fluid in 10 mL volumes[1]. |
References: [1]. Bennett AD, et al. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chroniccentral pain. Pain. 2000 May;86(1-2):163-75. |
Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist.
CGRP-(8-37) is a truncated version of calcitonin gene-related peptide (CGRP) that binds to the CGRP receptor with similar affinity but does not activate the receptor[1].
CGRP-(8-37) is effective in alleviating mechanical and thermal allodynia in a dose-dependent manner. The 50 nM dose is most efficacious for both forelimb and hindlimb responses. The period of efficacy is 10 min to onset for a duration of 20 min. Post-drug washout responses are not statistically significant compared to pre-drug responses[1]. Intrathecal administration of 5 nmol or 10 nmol of CGRP-(8-37), but not 1 nmol, induces a significant increase in hindpaw withdrawal latency. Intrathecal administration of CGRP-(8-37) not only reverses the SP-induced decrease in latency to both withdrawal responses but also mediates a significant increase in response latency compared to basal levels[2].
References:
[1]. Bennett AD, et al. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chroniccentral pain. Pain. 2000 May;86(1-2):163-75.
[2]. Yu LC, et al. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawalresponses in rats. Brain Res. 1994 Aug 8;653(1-2):223-30.
Cas No. | 129121-73-9 | SDF | |
Chemical Name | (3S,4Z,6S,7Z,9S,10Z,12S,13Z,16Z,19Z,21S,22Z,24S,25Z,27S,28Z,30S,31Z,33S,34Z,37Z,39S,40Z,42S,43Z,45S,46Z,48S,49Z,51S,52Z,54S)-48-((1H-imidazol-5-yl)methyl)-54-amino-6-(4-aminobutyl)-3-((Z)-(((S,Z)-1-(((S,Z)-1-(((S)-1-((S)-2-((1Z,3S,4Z,6S,7Z,9S,10Z,13Z,15S, | ||
Canonical SMILES | CC(C[C@@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])C(C)C)([H])[C@@](O)([H])C)([H])CC1=CN=CN1)([H])CCCNC(N)=N)([H])CC(C)C)([H])C)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/C/C(O | ||
Formula | C138H224N42O41 | M.Wt | 3127.51 |
Solubility | Soluble to 1 mg/ml in sterile water | Storage | -20°C, protect from light |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.3197 mL | 1.5987 mL | 3.1974 mL |
5 mM | 0.0639 mL | 0.3197 mL | 0.6395 mL |
10 mM | 0.032 mL | 0.1599 mL | 0.3197 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *